Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Bluebird Bio Inc. (Nasdaq: BLUE)

With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio’s gene therapy clinical programs include its Lenti-D™ product candidate, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin™ BB305 product candidate, currently in three clinical studies for the treatment of transfusion-dependent ß-thalassemia, and severe sickle cell disease. bluebird bio’s oncology pipeline is built upon the company’s leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program partnered with Celgene. bb2121 is currently being studied in a Phase 1 trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across the company’s pipeline. *


Period Start 2014-06-16 existent
  Group Bluebird Bio (Group)
Products Industry gene therapy
  Industry 2 Zynteglo™ (autologous CD34+ cells encoding ß A-T87Q-globin gene, formerly LentiGlobin™)
Person Person Leschly, Nick (Bluebird Bio 201606 CEO)
Region Region Cambridge, MA
  Country United States (USA)
  Street 150 2nd Street
  City 02141 Cambridge, MA
  Tel +1-339-499-9300
    Address record changed: 2024-01-05
Basic data Employees D: 101 to 500 (2023-01-31)
  Currency USD
  Annual sales 3,597,000 (revenues, total, consolidated (2022) 2022-12-31)
  Profit -266,578,000 (2022-12-31)
  Cash 113,006,000 (2022-12-31)
    * Document for »About Section«: 
Record changed: 2024-06-07


Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x200px

More documents for Bluebird Bio (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top